Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Madsbad et al
Always consult a qualified healthcare provider before making any health-related decisions
Sources Phase 2 Retatrutide Trial (NEJM) Triple hormone receptor agonist retatrutide for metabolic dysfunctionassociated steatotic liver disease Triple Agonism Review (PMC) Triple Agonism Based Therapies for Obesity Retatrutide Game Changer Review RetatrutideA Game Changer in Obesity Pharmacotherapy The Atlantic GLP3 Underground Market GoodRx Retatrutide Availability & Dosage Retatrutide for Weight Loss: Availability, Dosage, and More Phase 3 Trial Update (Clinical Trials Arena) Lillys triple G agonist boasts 28.7% weight loss in Phase III trial Retatrutide FDA Status 2026 Retatrutide FDA Approval Status 2026: Phase 3 Results Update GLP3 Retatrutide FAQ (Expert) GLP3 Retatrutide Peptide Expert FAQ Dr
References Pickart, L
Statistical significance was determined using two-tailed Students t- test for two-group comparisons or analysis of variance (Dunnetts test) for more than two group differences
Most cases occurred in patients who experienced dehydration from GI side effects
US$ 23.63
US$ 21.41
US$ 28.23
